MedTrace Logo

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

NCT00030303 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-04-28

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune response to kill cancer cells.

PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.

Conditions

Interventions

BIOLOGICAL

recombinant 70-kD heat-shock protein

Sponsors & Collaborators

  • UConn Health

    lead OTHER

Principal Investigators

  • Zihai Li, MD, PhD · UConn Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2004-01-31
Completion
2004-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00030303 on ClinicalTrials.gov